Please login to the form below

Not currently logged in
Email:
Password:

Summit appoints Pfizer/Bayer veteran as CMO

David Roblin to lead development of therapies for Duchenne muscular dystrophy and C.difficile

Summit David RoblinIndustry veteran Dr David Roblin has joined the Oxford, UK-based drug development and discovery company Summit as its chief medical officer.

Dr Roblin has years of senior research experience at major pharma firms, including serving as head of research, site director and chief medical officer for Europe R&D during a spell with Pfizer.

He was also head of ant-infectives at Bayer, where he led the development of several antiobiotics, including Avelox (moxifloxacin) and Cipro (ciprofloxacin).

This experience in anti-infectives will prove useful at Summit, with the company's research efforts including the development of treatments for C difficile infection in addition to potential thereapies for Duchenne muscular dystrophy.

"David brings considerable expertise in all aspects of drug development having been instrumental in the successful development of a number of important medicines,” said Summit's CEO Glyn Edwards.

“As our Duchenne muscular dystrophy and C difficile infection drug programmes go through patient clinical trials, David will make a major contribution to their successful development."

13th June 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics